![]() |
市場調査レポート
商品コード
1433294
自己創傷パッチの世界市場:2023-2030年Global Autologous Wound Patches Market 2023-2030 |
||||||
カスタマイズ可能
|
自己創傷パッチの世界市場:2023-2030年 |
出版日: 2023年12月01日
発行: Orion Market Research
ページ情報: 英文 210 Pages
納期: 2~3営業日
|
世界の自己創傷パッチ市場は、予測期間(2023-2030年)にCAGR 9.2%で成長すると予測されています。自己創傷パッチは、創傷治癒を促進し、合併症のリスクを低減することができるため、患者に新たな治療オプションを提供します。全身の皮膚損傷は、何百万人もの患者の日常生活を妨げ続け、入院の長期化、感染症、死亡の原因となっています。創傷治療器具の進歩により臨床現場は改善されたが、主にマクロスケールの創傷治癒と、その根底にあるミクロスケールの病態生理の治療に焦点が当てられてきました。様々な創傷治癒器具を用いた最適な治療戦略についてはコンセンサスが得られていないため、新たな治療法の開発が望まれています。
用途別では、慢性創傷サブセグメントが世界の自己創傷パッチ市場でかなりのシェアを占めると予想されています。このセグメントの成長は、慢性創傷、高度な包帯が調節不全の炎症相をターゲットにし、皮膚組織を置換し、感染から保護するなどのいくつかの要因に起因しています。糖尿病性創傷では、最近、急性炎症を誘発することで治癒プロセスを飛躍的に促進させることに注目が集まっています。肥満細胞安定剤の予防的投与と神経ペプチドサブスタンスPの放出は、ともに糖尿病マウスにおいて創傷後の強い炎症を誘発し、創傷の再上皮化を改善し、創傷治癒を促進しました。世界保健機関(WHO)によると、世界中で約4億2,200万人が糖尿病を患っており、その大半は低所得国と中所得国に住んでいます。毎年150万人が糖尿病が直接の原因で死亡しており、糖尿病の症例数と有病率はどちらも過去数十年にわたって着実に増加しています。
世界の自己創傷パッチ市場は、北米(米国、カナダ)、欧州(英国、イタリア、スペイン、ドイツ、フランス、その他欧州地域)、アジア太平洋地域(インド、中国、日本、韓国、その他アジア地域)、世界のその他の地域(中東とアフリカ、南米)を含む地域別にさらに細分化されています。なかでもアジア太平洋地域は、交通事故や外傷事故の増加に伴い、複雑な創傷を持つ患者数が増加していることから、世界市場で大きなシェアを占めると予想されています。自己創傷パッチは、組織の再生を促進し、損傷を容易に修復することができるため、こうしたタイプの創傷の治療に特に適しています。
すべての地域の中で、欧州地域は予測期間中にかなりのCAGRで成長すると予測されています。同地域の成長は、同地域における医療の進歩と技術革新に起因しています。治癒時間の短縮、痛みや不快感の軽減、使いやすさなどの特性が改善された、新しく革新的な自己創傷パッチの開発に注目が集まっています。例えば、2023年7月、患者自身の全血から作製される個別化された自己血創傷治療ソリューションであるレッドドレス社は、同社のActiGraft PRO製品が米国内で市販され、NCD 270.3およびG-0465 &G-0460コードを通じてメディケアおよびメディケア・アドバンテージから全国的に払い戻しを受けることができるようになったと発表しました。一旦適用されると、血餅は保護カバーとして機能し、身体の自然な創傷治癒反応をサポートします。糖尿病性足潰瘍、褥瘡、静脈性潰瘍、外傷性創傷、術後創傷など、治療が困難な様々な慢性創傷に使用できます。
Global Autologous Wound Patches Market Size, Share & Trends Analysis Report by Type (Platelet Rich Plasma and Platelet Rich Fibrin), by Application (Acute wound and chronic wound), and by End-User (Hospitals, Clinics, and Ambulatory Surgical Center), Forecast Period (2023-2030)
The global autologous wound patches market is anticipated to grow at a CAGR of 9.2% during the forecast period (2023-2030). Autologous wound patches offer new treatment option for patients, as they can help to accelerate wound healing and reduce the risk of complications. Skin injuries across the body continue to disrupt everyday life for millions of patients and result in prolonged hospital stays, infection, and death. Advances in wound healing devices have improved clinical practice but have mainly focused on treating macroscale healing versus underlying microscale pathophysiology. Consensus is lacking on optimal treatment strategies using a spectrum of wound healing products, which has motivated the design of new therapies.
The global autologous wound patches market is segmented on the type, application, and end-user. Based on the type, the market is sub-segmented into platelet rich plasma and platelet rich fibrin. Based on application, the market is sub-segmented into acute wound and chronic wound. Based on the end-user, the market is sub-segmented into a hospitals, clinics, and ambulatory surgical center. Among the type, the Platelet rich fibrin sub-segment is anticipated to hold a considerable share of the market, owing to factor which includes, it spun at a lower speed, which allows some of the white blood cells & stem cells to remain intact with the platelet layer, as a result, more healing factors are present in platelet rich fibrin patches, which supports faster healing of chronic wounds.
Among the application, the chronic wound sub-segment is expected to hold a considerable share of the global Autologous wound patches market. This segmental growth is attributed to several factor such as, chronic wounds, advanced bandages target the dysregulated inflammatory phase, replace skin tissue, and protect against infection. In diabetic wounds, recent attention focused on jump-starting the healing process by inducing acute inflammation. The preventive delivery of a mast cell stabilizer and the release of the neuropeptide substance P both induced strong inflammation after wounding, improved wound re-epithelialization, and accelerated wound healing in diabetic mice. According to World health organization, about 422 million people worldwide have diabetes, the majority living in low-and middle-income countries, and 1.5 million deaths are directly attributed to diabetes each year. Both the number of cases and the prevalence of diabetes have been steadily increasing over the past few decades.
The global autologous wound patches market is further segmented based on geography including North America (the US, and Canada), Europe (UK, Italy, Spain, Germany, France, and the Rest of Europe), Asia-Pacific (India, China, Japan, South Korea, and Rest of Asia), and the Rest of the World (the Middle East & Africa, and Latin America). Among these, Asia pacific is anticipated to hold a prominent share of the market across the globe, owing to Increasing number of road and traumatic accidents in the region, leading to a rise in the number of patients with complex wounds. Autologous wound patches are particularly suitable for treating these types of wounds, as they can help to promote tissue regeneration and repair the damage easily.
Among all regions, the European regions is anticipated to grow at a considerable CAGR over the forecast period. Regional growth is attributed to medical advancements and innovation in the region. There is a growing focus on developing new and innovative autologous wound patches with improved properties such as faster healing times, reduced pain and discomfort, and ease of use. For instance, In July 2023, RedDress, a personalized and autologous wound care solution created from patients own whole blood, announced that its ActiGraft PRO product is now commercially available throughout the US and is eligible for reimbursement nationally from Medicare and Medicare Advantage via NCD 270.3 and G-0465 & G-0460 codes. it enables health care providers to produce, 'in real time' in vitro blood clots from a patient's own blood. Once applied, the blood clot serves as a protective covering and supports the body's natural wound healing response. it can be used for a wide variety of hard-to-treat chronic wounds, including diabetic foot ulcers, pressure injuries, venous ulcers, traumatic wounds and post-surgical wounds.
The major companies serving the autologous wound patches market include Reapplix, PRP Concepts, RedDress, Nuo Therapeutics, and others. The market players are considerably contributing to the market growth by the adoption of various strategies including mergers and acquisitions, partnerships, collaborations, funding, and new product launches, to stay competitive in the market. For instance, In August 2023, RedDress, developers of the ActiGraft PRO system, a personalized and autologous wound care solution created from patients' own whole blood, announced that its ActiGraft PRO product is now available through Vizient, the nation's largest provider-driven healthcare performance improvement company. Additionally, it announced also established a strategic partnership with OneMed, part of the Asker Healthcare Group, to commercialize and distribute the ActiGraft system throughout Finland.